Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $21.11

Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Rating) has been assigned an average rating of “Hold” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $21.11.

A number of analysts have issued reports on the stock. initiated coverage on shares of Esperion Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. JPMorgan Chase & Co. raised Esperion Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 target price on the stock in a report on Wednesday, May 4th. Finally, HC Wainwright began coverage on Esperion Therapeutics in a research report on Thursday, March 10th. They issued a “buy” rating and a $22.00 target price on the stock.

Institutional investors have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in Esperion Therapeutics during the 1st quarter valued at $186,000. Royal Bank of Canada raised its holdings in shares of Esperion Therapeutics by 70.1% in the second quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 2,699 shares in the last quarter. ProShare Advisors LLC bought a new position in Esperion Therapeutics during the 4th quarter worth about $50,000. Spire Wealth Management purchased a new position in Esperion Therapeutics during the fourth quarter valued at approximately $51,000. Finally, Principal Financial Group Inc. acquired a new stake in Esperion Therapeutics in the 1st quarter worth approximately $49,000.

Shares of NASDAQ:ESPR traded down $0.11 during trading on Friday, hitting $5.52. 42,188 shares of the company’s stock were exchanged, compared to its average volume of 1,343,051. The business’s 50-day simple moving average is $5.47 and its 200 day simple moving average is $5.34. The company has a market cap of $347.80 million, a price-to-earnings ratio of -0.81 and a beta of 0.43. Esperion Therapeutics has a 52-week low of $3.28 and a 52-week high of $26.77.

Esperion Therapeutics (NASDAQ:ESPRGet Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.11. The company had revenue of $18.84 million for the quarter, compared to analysts’ expectations of $15.41 million. The company’s quarterly revenue was up 136.1% compared to the same quarter last year. During the same period last year, the business earned ($3.50) earnings per share. Research analysts expect that Esperion Therapeutics will post -3.73 EPS for the current fiscal year.

Esperion Therapeutics Company Profile (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

See Also

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with's FREE daily email newsletter.